GO
Loading...

Enter multiple symbols separated by commas

Valeant Pharmaceuticals International Inc

More

  • May 20- Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter. A sale could value Amoun at $700 million to $800 million, Bloomberg reported. Should Amoun fail to find a buyer, it may consider an...

  • Valeant CEO expects sharp rise in Asia revenue by 2020 Tuesday, 19 May 2015 | 1:04 PM ET

    MONTREAL, May 19- Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020, Chief Executive Michael Pearson said on Tuesday. Asia, which is expected to generate about $1 billion in sales this year, "has the best growth prospects of any region in the...

  • May 18- TPG Capital LP may have helped its own campaign to go public after pulling Par Pharmaceutical Holdings Inc's IPO. TPG was preparing to begin an IPO investor roadshow for Par Pharmaceutical Holdings before it agreed to sell the generics drugmaker to Endo International Plc for around $8 billion. Founded in 1992 by David Bonderman and James Coulter, San...

  • TRENTON, N.J.— Drugmaker Endo International PLC is climbing toward the top of the steadily consolidating generic medicine business with a deal to buy Par Pharmaceutical Holdings Inc. for about $8.05 billion. In the U.S., that includes the biggest health insurers and two pharmacy benefit managers, Express Scripts Holding Co. and CVS Health Corp. In other...

  • BOSTON, May 15- Wall Street's savviest investors are picking sides on Bill Ackman's new bet on Valeant Pharmaceuticals International Inc, with BlueMountain Capital and T. Rowe Price adding money, while Viking Global Investors and Jana Partners cut stakes. T. Rowe Price bought an additional 2.3 million Valeant shares, raising its stake 12 percent to 20.1 million...

  • *Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...

  • Shares of Actavis PLC rose $9.43, or 3.2 percent, to $302.25 in afternoon trading Monday. Actavis closed its deal to buy Allergan in March after outbidding drugmaker Valeant Pharmaceuticals for the company. Actavis expects full-year earnings in the range of $17 to $18.50 per share, with revenue in the range of $20.5 billion to $21 billion.

  • The company said it expects 2015 revenue of $10.4- $10.6 billion, up from its previous estimate of $9.2- $9.3 billion. Valeant, which lost a bid for Botox maker Allergan Inc in November, said sales from the United States rose to $1.40 billion in the first quarter ended March 31. Net income attributable to shareholders was $73.7 million, or 21 cents per share, in the...

  • Valeant Pharma posts profit, says CFO to step down Wednesday, 29 Apr 2015 | 6:28 AM ET

    April 29- Canadian drugmaker Valeant Pharmaceuticals International Inc reported a quarterly profit, compared with a year-ago loss, driven by higher demand in the United States. The company also said Chief Financial Officer Howard Schiller would step down. Net income attributable to shareholders was $73.7 million, or 21 cents per share, in the first quarter...

  • April 21- Some of the top investors at Mylan NV, including Paulson& Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter. Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania- based company.

  • Teva makes $40B bid for Mylan Tuesday, 21 Apr 2015 | 8:49 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10.

  • The surprising reason banks are seeing talent flee Tuesday, 14 Apr 2015 | 7:30 AM ET
    Wall Street

    Several high-ranking bankers have left their jobs at major investment banks in the last 13 months amid a surge in U.S. health care deal activity.

  • Hedge fund machines cash in—again Thursday, 9 Apr 2015 | 12:46 PM ET
    Systematica Investments' CEO Leda Braga in their offices, Geneva, Switzerland last February.

    Hedge funds that catch macroeconomic trends using algorithms made a killing in the first quarter, besting other investing styles.

  • Billionaire John Paulson up 14% on M&A bets Tuesday, 31 Mar 2015 | 7:20 AM ET
    John Pauslon

    Billionaire investor John Paulson is starting off 2015 with a bang — thanks to a heated merger market.

  • Iron ore gloom chills Fortescue bond sale Thursday, 19 Mar 2015 | 4:37 AM ET

    NEW YORK/ MELBOURNE, March 19- A treacherous snowstorm snarled flights the day Fortescue Metals Group's CFO touched down in New York on a mission to tap the loan market for $2.5 billion to help the world's no.4 iron ore miner ride out collapsing iron ore prices. The timing was terrible- as Stephen Pearce battled through the frigid Manhattan weather, another squall...

  • Junk bond market defies skeptics Wednesday, 18 Mar 2015 | 11:28 AM ET
    Traders work on the floor of the New York Stock Exchange.

    There has been no sting in the tail for investors willing to bet on US high-yield bonds during 2015, the Financial Times reports.

  • After-hours buzz: Jumei, American Air & more Monday, 16 Mar 2015 | 5:46 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Monday's after-hours buzz: Jumei, American Air & more.

  • March 16- U.S. stocks rallied on Monday as the U.S. dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike. The S&P healthcare sector led gains in the S&P 500. It jumped 2.2 percent, helped by a 5.7 percent price increase in shares of Amgen to $163.03, following promising data in studies of a new class of...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher as investors cheered a pause in the dollar rally and eyed renewed weakness in oil prices ahead of Wednesday's Fed meeting.

  • "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. The S&P healthcare sector was up 1.9 percent, helped by a 3.6 percent price increase in shares of Amgen to $159.73, following promising data in studies of a new class of cholesterol-reducing drugs.